iShares US Pharmaceuticals ETF (IHE)
63.43
+0.70
(+1.12%)
USD |
NYSEARCA |
Apr 26, 16:00
63.43
0.00 (0.00%)
After-Hours: 18:39
Price Chart
Key Stats
| Net Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
|---|---|---|---|
| 0.40% | -0.20% | 650.54M | 86178.93 |
| Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (Since Inception) |
| 1.43% | 46.00% | 177.96M | Upgrade |
Basic Info
| Investment Strategy | |
| The investment seeks to track the investment results of the Dow Jones U.S. Select Pharmaceuticals Index. The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index measures the performance of the pharmaceuticals sector of the U.S. equity market. The underlying index includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines. The fund is non-diversified. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Large Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Global Category Name | Healthcare Sector Equity |
| YCharts Categorization | Healthcare Equity |
| YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | iShares |
| Prospectus Benchmark Index | |
| DJ US Select Pharms TR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Greg Savage | 16.26 yrs |
| Jennifer Hsui | 11.59 yrs |
| Paul Whitehead | 2.25 yrs |
Performance Versus Category
As of April 25, 2024. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of April 25, 2024.
Basic Info
| Investment Strategy | |
| The investment seeks to track the investment results of the Dow Jones U.S. Select Pharmaceuticals Index. The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index measures the performance of the pharmaceuticals sector of the U.S. equity market. The underlying index includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines. The fund is non-diversified. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Large Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Global Category Name | Healthcare Sector Equity |
| YCharts Categorization | Healthcare Equity |
| YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | iShares |
| Prospectus Benchmark Index | |
| DJ US Select Pharms TR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Greg Savage | 16.26 yrs |
| Jennifer Hsui | 11.59 yrs |
| Paul Whitehead | 2.25 yrs |